Cargando…

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study

OBJECTIVE: PsA is a chronic inflammatory disease in which the skin and joints are affected. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one...

Descripción completa

Detalles Bibliográficos
Autores principales:	Östör, Andrew, Van den Bosch, Filip, Papp, Kim, Asnal, Cecilia, Blanco, Ricardo, Aelion, Jacob, Lu, Wenjing, Wang, Zailong, Soliman, Ahmed M, Eldred, Ann, Padilla, Byron, Kivitz, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234194/ https://www.ncbi.nlm.nih.gov/pubmed/36282537 http://dx.doi.org/10.1093/rheumatology/keac605

Ejemplares similares

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
por: Östör, Andrew, et al.
Publicado: (2022)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
por: Ostor, Andrew J K, et al.
Publicado: (2022)

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
por: Kristensen, Lars Erik, et al.
Publicado: (2022)

The effect of risankizumab on achieving minimal clinically important differences in patient‐reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2
por: Kristensen, L.E., et al.
Publicado: (2022)

Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1
por: Kristensen, Lars Erik, et al.
Publicado: (2022)

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
por: Kristensen, Lars Erik, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
por: Mease, Philip J., et al.
Publicado: (2022)

Commentary: The genius of Ake Senning
por: Huddleston, Charles B.
Publicado: (2020)

Homage to Professor Hans-Åke Gustafsson
Publicado: (2010)

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
por: Thakre, Neha, et al.
Publicado: (2022)

I$\tau$ $\tau$akes a Village
por: Mancinelli, Giampiero
Publicado: (2019)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
por: Caldarola, Giacomo, et al.
Publicado: (2023)

Sweden @CERN & ALICE Experiment - Hans-Ake Gustafsson
por: CERN. Geneva
Publicado: (2006)

Risankizumab for psoriasis
Publicado: (2020)

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
por: Papp, Kim A., et al.
Publicado: (2021)

Program Bytes - Satellite Meetings, SIGs, and AKEs at ISMB 2016
por: Fogg, Christiana
Publicado: (2016)

Program Bytes: Satellite Meetings, SIGs, and AKEs at ISMB 2016
por: Fogg, Christiana N., et al.
Publicado: (2016)

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
por: Wells, Alvin F, et al.
Publicado: (2018)

Antioxidant and Lipoxygenase Inhibitory Activities of Essential Oils from Endemic Plants of Côte d’Ivoire: Zanthoxylum mezoneurispinosum Ake Assi and Zanthoxylum psammophilum Ake Assi
por: Tanoh, Evelyne A., et al.
Publicado: (2019)

Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

Review of Nephelium lappaceum and Nephelium ramboutan-ake: A High Potential Supplement
por: Tsong, Jia Ling, et al.
Publicado: (2021)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study
por: Diotallevi, Federico, et al.
Publicado: (2023)

“Real men” need keepsakes too: both Italian men and women use inanimate objects to cope with separation
por: Niemyjska, Aleksandra, et al.
Publicado: (2021)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Risankizumab: COVID-19: case report
Publicado: (2021)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Interrater and Intrarater Reliability of the Active Knee Extension (AKE) Test among Healthy Adults
por: Hamid, Mohamad Shariff A, et al.
Publicado: (2013)

AKE - the Accelerated k-mer Exploration web-tool for rapid taxonomic classification and visualization
por: Langenkämper, Daniel, et al.
Publicado: (2014)

Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study
por: Gargiulo, Luigi, et al.
Publicado: (2022)

Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
por: Papp, Kim A., et al.
Publicado: (2021)

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Rapidly and successful improvement of nail psoriasis with risankizumab
por: Orsini, Diego, et al.
Publicado: (2023)

Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52
por: Behrens, Frank, et al.
Publicado: (2021)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f3rebqlja3e71g8gf58uig2fch